1. Home
  2. CDT vs VIVS Comparison

CDT vs VIVS Comparison

Compare CDT & VIVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CDT
  • VIVS
  • Stock Information
  • Founded
  • CDT 2019
  • VIVS 2007
  • Country
  • CDT United States
  • VIVS United States
  • Employees
  • CDT N/A
  • VIVS N/A
  • Industry
  • CDT Biotechnology: Pharmaceutical Preparations
  • VIVS Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • CDT Health Care
  • VIVS Health Care
  • Exchange
  • CDT Nasdaq
  • VIVS Nasdaq
  • Market Cap
  • CDT 5.2M
  • VIVS 5.0M
  • IPO Year
  • CDT N/A
  • VIVS N/A
  • Fundamental
  • Price
  • CDT $1.93
  • VIVS $2.21
  • Analyst Decision
  • CDT
  • VIVS
  • Analyst Count
  • CDT 0
  • VIVS 0
  • Target Price
  • CDT N/A
  • VIVS N/A
  • AVG Volume (30 Days)
  • CDT 290.9K
  • VIVS 70.9K
  • Earning Date
  • CDT 08-11-2025
  • VIVS 08-05-2025
  • Dividend Yield
  • CDT N/A
  • VIVS N/A
  • EPS Growth
  • CDT N/A
  • VIVS N/A
  • EPS
  • CDT N/A
  • VIVS N/A
  • Revenue
  • CDT N/A
  • VIVS $144,000.00
  • Revenue This Year
  • CDT N/A
  • VIVS $42.38
  • Revenue Next Year
  • CDT N/A
  • VIVS $15.42
  • P/E Ratio
  • CDT N/A
  • VIVS N/A
  • Revenue Growth
  • CDT N/A
  • VIVS 32.11
  • 52 Week Low
  • CDT $1.90
  • VIVS $1.41
  • 52 Week High
  • CDT $622.50
  • VIVS $21.96
  • Technical
  • Relative Strength Index (RSI)
  • CDT 28.61
  • VIVS N/A
  • Support Level
  • CDT $1.94
  • VIVS N/A
  • Resistance Level
  • CDT $2.31
  • VIVS N/A
  • Average True Range (ATR)
  • CDT 0.16
  • VIVS 0.00
  • MACD
  • CDT 0.04
  • VIVS 0.00
  • Stochastic Oscillator
  • CDT 7.02
  • VIVS 0.00

About CDT Conduit Pharmaceuticals Inc.

Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.

About VIVS VivoSim Labs Inc. Common Stock

VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.

Share on Social Networks: